The COVID-19 Prevention Network (CoVPN) was established by the National Institute
of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to
enroll thousands of volunteers for large-scale Phase 3 clinical trials testing a variety of investigational vaccines and monoclonal antibodies to protect people from COVID-19. The network merges four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network (HVTN), based in Seattle, WA; the HIV Prevention Trials Network (HPTN), based in Durham, NC; the Infectious Diseases Clinical Research Consortium (IDCRC), based in Atlanta, GA; and the AIDS Clinical Trials Group, based in Los Angeles, CA. The individual networks will continue to perform clinical trials for HIV vaccines and prevention and other infectious diseases, in addition to their new COVID roles.